Online inquiry

IVTScrip™ mRNA-Anti-ITGA4&ITGB7, AMG 181(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2471MR)

This product GTTS-WQ2471MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ITGA4&ITGB7 gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000885.6; NM_000889.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3676; 3695
UniProt ID P13612; P26010
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGA4&ITGB7, AMG 181(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2471MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8462MR IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HTI-1088
GTTS-WQ6353MR IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CSL-362-AML
GTTS-WQ9174MR IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IMGN-529
GTTS-WQ89MR IVTScrip™ mRNA-Anti-KDR, 1121B(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA 1121B
GTTS-WQ6310MR IVTScrip™ mRNA-Anti-TNFRSF10B, CS-1008(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CS-1008
GTTS-WQ5736MR IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CEA-IL-2v
GTTS-WQ8621MR IVTScrip™ mRNA-Anti-CD33, HuM195(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA HuM195
GTTS-WQ11973MR IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MM-005
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW